Lloyd King

567 citations

24 papers · 370 indexed · h-index 10

Impact in

Pharmacology top 10%
- Pharmacogenetics and Drug Metabolism
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research

Papers in ⓘ

Pharmacology 6
- Pharmacogenetics and Drug Metabolism 5
Transplantation 1

Co-authors: David P. Humphreys (6 shared papers)Nenad Manevski (2 shared papers)Bryan John Smith (5 shared papers)Fabien Lecomte (2 shared papers)William R. Pitt (1 shared paper)Paul E. Stephens (4 shared papers)Andrew P. Chapman (3 shared papers)David Glover (2 shared papers)
Journals: Drug Metabolism Reviews (4 papers)Protein Expression and Purification (3 papers)The American Journal of Gastroenterology (3 papers)Protein Engineering Design and Selection (2 papers)Drug Metabolism and Disposition (2 papers)
Partner nations: United Kingdom United States Belgium

In The Last Decade

Lloyd King

23 papers receiving 347 citations

Peers

Countries citing papers authored by Lloyd King

Since Specialization

Citations

This map shows the geographic impact of Lloyd King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd King more than expected).

Fields of papers citing papers by Lloyd King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd King. The network helps show where Lloyd King may publish in the future.

Co-authors

The 25 scholars most cited alongside Lloyd King, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lloyd King Line = papers co-authored together Lloyd King links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery Journal of Medicinal Chemistry ·Nenad Manevski, Lloyd King, William R. Pitt, Fabien Lecomte, Francesca Toselli	2019	74
2	High-Level Periplasmic Expression in Escherichia coli Using a Eukaryotic Signal Peptide: Importance of Codon Usage at the 5′ End of the Coding Sequence Protein Expression and Purification ·David P. Humphreys, Mukesh Sehdev, Andrew P. Chapman, Ravindra Ganesh, Bryan John Smith, Lloyd King, David Glover, Dominic G. Reeks, Paul E. Stephens	2000	55
3	A plasmid system for optimization of Fab′ production in Escherichia coli: importance of balance of heavy chain and light chain synthesis Protein Expression and Purification ·David P. Humphreys, Bruce Carrington, Leigh C. Bowering, Ravindra Ganesh, Mukesh Sehdev, Bryan John Smith, Lloyd King, Dominic G. Reeks, Alastair D. G. Lawson, Andrew G. Popplewell	2002	39
4	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase Bioorganic & Medicinal Chemistry Letters ·John Porter, Simon Lumb, Richard J. Franklin, Jose M. Gascon-Simorte, Mark Calmiano, Kelly Le Riche, Bénédicte Lallemand, Jean Keyaerts, Helen Edwards, Alison Maloney, Jean Delgado, Lloyd King, Anne Foley, Fabien Lecomte, James Reuberson, Christoph Meier, Mark Batchelor	2009	33
5	F(ab′)2 molecules made from Escherichia coli produced Fab′ with hinge sequences conferring increased serum survival in an animal model Journal of Immunological Methods ·David P. Humphreys, Olivia M. Vetterlein, Andrew P. Chapman, David J. King, Pari Antoniw, Amanda J. Suitters, Dominic G. Reeks, Ted A.H. Parton, Lloyd King, Bryan John Smith, Volker Lang, Paul E. Stephens	1998	24
6	Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery Drug Metabolism and Disposition ·Mari Davies, Prabha Peramuhendige, Lloyd King, Melanie Golding, Apoorva Kotian, Mark Penney, Syeda A.B. Shah, Nenad Manevski	2020	22
7	Efficient site specific removal of a C-terminal FLAG fusion from a Fab′ using copper(II) ion catalysed protein cleavage Protein Engineering Design and Selection ·David P. Humphreys, Bryan John Smith, Lloyd King, Shauna West, Dominic G. Reeks, Paul E. Stephens	1999	21
8	Improved efficiency of site-specific copper(II) ion-catalysed protein cleavage effected by mutagenesis of cleavage site Protein Engineering Design and Selection ·David P. Humphreys, Lloyd King, Shauna West, Andrew P. Chapman, Mukesh Sehdev, Matthew W. Redden, David Glover, Bryan John Smith, Paul E. Stephens	2000	19
9	Setup of human liver-chips integrating 3D models, microwells and a standardized microfluidic platform as proof-of-concept study to support drug evaluation SHILAP Revista de lepidopterología ·Benoit Cox, Patrick Barton, Reiner Class, Hannah Coxhead, Claude Delatour, Eric Gillent, Jamie Henshall, Emre M. Isin, Lloyd King, Jean‐Pierre Valentin	2022	17
10	A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation Drug Metabolism and Disposition ·Markus Walles, Michael J. Berna, Wenying Jian, Simon Hauri, Shawna Hengel, Lloyd King, John C. Tran, Cong Wei, Keyang Xu, Xiaochun Zhu	2022	10
11	Engineering of Escherichia coli to improve the purification of periplasmic Fab′ fragments: changing the pI of the chromosomally encoded PhoS/PstS protein Protein Expression and Purification ·David P. Humphreys, Sam Heywood, Lloyd King, Leigh C. Bowering, James P. Turner, Sarah E Lane	2004	9
12	Introduction of A Routine Quan/Qual Approach Into Research DMPK: Experiences and Evolving Strategies Bioanalysis ·Lloyd King, Apoorva Kotian, Mark Jairaj	2014	9
13	The PEG Moiety of Certolizumab Pegol is Rapidly Cleared From the Blood of Humans by the Kidneys Once it is Cleaved From the Fabʼ Inflammatory Bowel Diseases ·Ted A.H. Parton, Lloyd King, Adwoa Parker, Andrew Nesbitt	2009	8
14	Novel advances in biotransformation and bioactivation research – 2020 year in review Drug Metabolism Reviews ·S. Cyrus Khojasteh, Upendra A. Argikar, James P. Driscoll, Carley J. S. Heck, Lloyd King, Klarissa D. Jackson, Wenying Jian, Amit S. Kalgutkar, Grover P. Miller, Valerie M. Kramlinger, Ivonne M.C.M. Rietjens, Aaron M. Teitelbaum, Kai Wang, Cong Wei	2021	6
15	P068 INVESTIGATION OF THE DISTRIBUTION AND ELIMINATION OF THE PEG COMPONENT OF CERTOLIZUMAB PEGOL IN RATS Ted A.H. Parton, Lloyd King, Judith van Asperen, Sam Heywood, Andrew Nesbitt	2008	6
16	SHORT COMMUNICATION: The in vitro metabolic activation of the 11-trifluoromethyl analogue of the potent carcinogen 15, 16-dihydro-11-methyl-cyclopenta[a]-phenanthren-17-one to mutagens Carcinogenesis ·Gary W. Boyd, Helmut H. Zepik, Lloyd King, Costas Ioannides, Maurice M. Coombs	1993	4
17	Biotransformation research advances – 2022 year in review Drug Metabolism Reviews ·S. Cyrus Khojasteh, Upendra A. Argikar, Lionel Cheruzel, Sungjoon Cho, Rachel D. Crouch, Deepika Dhaware, Carley J. S. Heck, Kevin M. Johnson, Amit S. Kalgutkar, Lloyd King, Joyce Liu, Bin Ma, Hlaing Maw, Grover P. Miller, Herana Kamal Seneviratne, Ryan Takahashi, Shuai Wang, Cong Wei, Klarissa D. Jackson	2023	4
18	Biotransformation novel advances – 2021 year in review Drug Metabolism Reviews ·S. Cyrus Khojasteh, Upendra A. Argikar, Sungjoon Cho, Rachel D. Crouch, Carley J. S. Heck, Kevin M. Johnson, Amit S. Kalgutkar, Lloyd King, Hlaing Maw, Herana Kamal Seneviratne, Shuai Wang, Cong Wei, Donglu Zhang, Klarissa D. Jackson	2022	3
19	A mechanistic modelling approach for the determination of the mechanisms of inhibition by cyclosporine on the uptake and metabolism of atorvastatin in rat hepatocytes using a high throughput uptake method Xenobiotica ·Simon J. Carter, Alex S. Ferecskó, Lloyd King, Karelle Ménochet, Ted A.H. Parton, Michael J. Chappell	2019	3
20	Investigation of the Distribution and Elimination of the PEG Component of Certolizumab Pegol in Rats The American Journal of Gastroenterology ·Ted A.H. Parton, Lloyd King, Judith van Asperen, Sam Heywood, Andrew Nesbitt	2008	1

About Lloyd King

Lloyd King is a scholar working on Pharmacology, Transplantation, Hepatology, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 24 papers that have together received 370 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Metabolomics and Mass Spectrometry Studies (3 papers), Protein purification and stability (3 papers), RNA and protein synthesis mechanisms (3 papers), Bacterial Genetics and Biotechnology (2 papers), Toxin Mechanisms and Immunotoxins (2 papers) and Liver physiology and pathology (2 papers). The work is most often cited by research in Pharmacology (51 citations), Radiology, Nuclear Medicine and Imaging (92 citations), Molecular Biology (247 citations), Pharmaceutical Science (17 citations) and Biotechnology (24 citations). Lloyd King has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include David P. Humphreys, Nenad Manevski, Bryan John Smith, Fabien Lecomte, William R. Pitt, Paul E. Stephens, Andrew P. Chapman, David Glover, Shauna West and Andrew Nesbitt. Their work appears in journals such as Drug Metabolism Reviews, Protein Expression and Purification, The American Journal of Gastroenterology, Protein Engineering Design and Selection and Drug Metabolism and Disposition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact